Pongpak Pongphitcha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Pongpak Pongphitcha has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Ampaiwan Chuansumrit
Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Nongnuch Sirachainan
Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
3 shared publications - Somchai Chutipongtanate
Department of Environmental and Public Health Sciences, University of Cincinnati, Cincinnati, OH
2 shared publications - Suradej Hongeng
Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 shared publications - Werasak Sasanakul
Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2 shared publications - Amber Afzal
Department of Medicine Washington University School of Medicine St. Louis Missouri USA
1 shared publication
Latest Publications
- Open Access
- 8 April 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (3) , 102847
Vitamin K deficiency bleeding in children with cholestatic liver disease: a systematic review and meta-analysis
- 8 April 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (3) , 102847
Open AccessVitamin K deficiency bleeding in children with cholestatic liver disease: a systematic review and meta-analysis
- 2 October 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (1) , 130-139
Application of Gene Expression Microarray for the Classification of Ph‐Like B‐Cell Acute Lymphoblastic Leukemia
Introduction: Ph‐like ALL has gene expression profile similar to Ph‐positive ALL but without the BCR::ABL1 fusion. The disease presents higher rates of severe clinical features and is associated with unfavorable outcomes. There is still no standard pipeline for molecular characterization of the disease, and no valid predictor gene panel is available worldwide.Methods: We performed expression microarray on 25 B‐cell ALL and 6 Ph‐positive B‐cell ALL to cluster and identify the transcriptional signature of Ph‐like ALL. qRT‐PCR was used to confirm the expression of candidate genes.Results: Four out of 25 samples (16%) shared gene expression signatures related to and clustered with control Ph‐positive samples. Analysis of genes differentially expressed in Ph‐like B‐cell ALL and evidentially functional in normal blood cell development and leukemogenesis, we selected genes as potential biomarkers for Ph‐like B‐cell ALL in our dataset: ADGRE2, CD9, EPHA7, FAM129C, TCL1A, and VPREB1. Those genes were filtered by Ph‐like gene signatures obtained from distinct reliable data, resulting in five genes, CA6, CHN2, JAK1, JCHAIN, and PON2, selected for validation by qRT‐PCR. The Ct values of genes, including CA6 (p = 0.0017), PON2 (p = 0.0210), TCL1A (p = 0.0064), and VPREB1 (p = 0.0338), were significant in Ph‐like ALL. GSEA analysis identified VPREB1 as enrichment in the KRAS signaling pathway, and several genes that interact with VPREB1 were reported as critical molecules involved in the leukemogenesis of B‐cell ALL.Conclusion: In summary, we demonstrate using a gene expression microarray for classifying Ph‐like B‐cell ALL and highlight VPREB1 as a potential biomarker for this disease.
- 2 October 2024
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (1) , 130-139
Application of Gene Expression Microarray for the Classification of Ph‐Like B‐Cell Acute Lymphoblastic Leukemia
Introduction: Ph‐like ALL has gene expression profile similar to Ph‐positive ALL but without the BCR::ABL1 fusion. The disease presents higher rates of severe clinical features and is associated with unfavorable outcomes. There is still no standard pipeline for molecular characterization of the disease, and no valid predictor gene panel is available worldwide.Methods: We performed expression microarray on 25 B‐cell ALL and 6 Ph‐positive B‐cell ALL to cluster and identify the transcriptional signature of Ph‐like ALL. qRT‐PCR was used to confirm the expression of candidate genes.Results: Four out of 25 samples (16%) shared gene expression signatures related to and clustered with control Ph‐positive samples. Analysis of genes differentially expressed in Ph‐like B‐cell ALL and evidentially functional in normal blood cell development and leukemogenesis, we selected genes as potential biomarkers for Ph‐like B‐cell ALL in our dataset: ADGRE2, CD9, EPHA7, FAM129C, TCL1A, and VPREB1. Those genes were filtered by Ph‐like gene signatures obtained from distinct reliable data, resulting in five genes, CA6, CHN2, JAK1, JCHAIN, and PON2, selected for validation by qRT‐PCR. The Ct values of genes, including CA6 (p = 0.0017), PON2 (p = 0.0210), TCL1A (p = 0.0064), and VPREB1 (p = 0.0338), were significant in Ph‐like ALL. GSEA analysis identified VPREB1 as enrichment in the KRAS signaling pathway, and several genes that interact with VPREB1 were reported as critical molecules involved in the leukemogenesis of B‐cell ALL.Conclusion: In summary, we demonstrate using a gene expression microarray for classifying Ph‐like B‐cell ALL and highlight VPREB1 as a potential biomarker for this disease.
- 23 May 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 1092-1095
Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease
- 23 May 2024
- Published by Wiley in Haemophilia
- Vol. 30 (4) , 1092-1095
Alleviated bleeding phenotypes in a child with severe haemophilia A and thalassemia disease
- Open Access
Extracellular Vesicles for Childhood Cancer Liquid Biopsy
Liquid biopsy involves the utilization of minimally invasive or noninvasive techniques to detect biomarkers in biofluids for disease diagnosis, monitoring, or guiding treatments. This approach is promising for the early diagnosis of childhood cancer, especially for brain tumors, where tissue biopsies are more challenging and cause late detection. Extracellular vesicles offer several characteristics that make them ideal resources for childhood cancer liquid biopsy. Extracellular vesicles are nanosized particles, primarily secreted by all cell types into body fluids such as blood and urine, and contain molecular cargos, i.e., lipids, proteins, and nucleic acids of original cells. Notably, the lipid bilayer-enclosed structure of extracellular vesicles protects their cargos from enzymatic degradation in the extracellular milieu. Proteins and nucleic acids of extracellular vesicles represent genetic alterations and molecular profiles of childhood cancer, thus serving as promising resources for precision medicine in cancer diagnosis, treatment monitoring, and prognosis prediction. This review evaluates the recent progress of extracellular vesicles as a liquid biopsy platform for various types of childhood cancer, discusses the mechanistic roles of molecular cargos in carcinogenesis and metastasis, and provides perspectives on extracellular vesicle-guided therapeutic intervention. Extracellular vesicle-based liquid biopsy for childhood cancer may ultimately contribute to improving patient outcomes.
Open AccessExtracellular Vesicles for Childhood Cancer Liquid Biopsy
Liquid biopsy involves the utilization of minimally invasive or noninvasive techniques to detect biomarkers in biofluids for disease diagnosis, monitoring, or guiding treatments. This approach is promising for the early diagnosis of childhood cancer, especially for brain tumors, where tissue biopsies are more challenging and cause late detection. Extracellular vesicles offer several characteristics that make them ideal resources for childhood cancer liquid biopsy. Extracellular vesicles are nanosized particles, primarily secreted by all cell types into body fluids such as blood and urine, and contain molecular cargos, i.e., lipids, proteins, and nucleic acids of original cells. Notably, the lipid bilayer-enclosed structure of extracellular vesicles protects their cargos from enzymatic degradation in the extracellular milieu. Proteins and nucleic acids of extracellular vesicles represent genetic alterations and molecular profiles of childhood cancer, thus serving as promising resources for precision medicine in cancer diagnosis, treatment monitoring, and prognosis prediction. This review evaluates the recent progress of extracellular vesicles as a liquid biopsy platform for various types of childhood cancer, discusses the mechanistic roles of molecular cargos in carcinogenesis and metastasis, and provides perspectives on extracellular vesicle-guided therapeutic intervention. Extracellular vesicle-based liquid biopsy for childhood cancer may ultimately contribute to improving patient outcomes.
- 26 October 2022
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (1) , e109-e118
Response to Prolonged Duration of Therapeutic Dose Oral Iron Therapy in a Girl With Novel TMPRSS6 Gene Variants: A Case Report and Review Literature
Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by mutations in the TMPRSS6 gene, which impair iron homeostasis. We reported a 4-year-old girl who presented with a 1-year history of iron deficiency anemia. Her hemoglobin level increased from 6.5 g/dL to 12.6 g/dL with a prolonged duration of therapeutic dose oral iron therapy (5 mg/kg/d), and the level remained quite stable during the therapy. Genetic analysis of the TMPRSS6 gene revealed compound heterozygotes of 2 novel pathogenic variants: c.811C> T (NM_153609.3) in exon 7 (NP_705837: p.R271Ter) and c.1254C> G in exon 11 (p.Y418Ter). The results highlight the significance of genetic investigation and long-term iron therapy in iron-refractory iron deficiency anemia patients.
- 26 October 2022
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 45 (1) , e109-e118
Response to Prolonged Duration of Therapeutic Dose Oral Iron Therapy in a Girl With Novel TMPRSS6 Gene Variants: A Case Report and Review Literature
Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by mutations in the TMPRSS6 gene, which impair iron homeostasis. We reported a 4-year-old girl who presented with a 1-year history of iron deficiency anemia. Her hemoglobin level increased from 6.5 g/dL to 12.6 g/dL with a prolonged duration of therapeutic dose oral iron therapy (5 mg/kg/d), and the level remained quite stable during the therapy. Genetic analysis of the TMPRSS6 gene revealed compound heterozygotes of 2 novel pathogenic variants: c.811C> T (NM_153609.3) in exon 7 (NP_705837: p.R271Ter) and c.1254C> G in exon 11 (p.Y418Ter). The results highlight the significance of genetic investigation and long-term iron therapy in iron-refractory iron deficiency anemia patients.
- 13 May 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (9) , e29757
Treatment outcomes among high‐risk neuroblastoma patients receiving non‐immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group
Background: Neuroblastoma is the most common extracranial malignant solid tumor during childhood. Despite intensified treatment, patients with high‐risk neuroblastoma (HR‐NBL) still carry a dismal prognosis. The Thai Pediatric Oncology Group (ThaiPOG) proposed the use of a multimodality treatment to improve outcomes of HR‐NBL in non‐immunotherapy settings.Methods: Patients with HR‐NBL undergoing ThaiPOG protocols (ThaiPOG‐NB‐13HR or ‐18HR) between 2013 and 2019 were retrospectively reviewed. Patient demographic data, treatment modalities, outcomes, and prognostic factors were evaluated and analyzed.Results: A total of 183 patients with HR‐NBL undergoing a topotecan containing induction regimen were enrolled in this study. During the consolidation phase (n = 169), 116 patients (68.6%) received conventional chemotherapy, while 53 patients (31.4%) underwent hematopoietic stem cell transplantation (HSCT). The 5‐year overall survival (OS) and event‐free survival (EFS) were 41.2% and 22.8%, respectively. Patients who underwent HSCT had more superior 5‐year EFS (36%) than those who received chemotherapy (17.1%) (p = .041), although they both performed similarly in 5‐year OS (48.7% vs. 39.8%, p = .17). The variation of survival outcomes was observed depending on the number of treatment modalities. HSCT combined with metaiodobenzylguanidine (MIBG) treatment and maintenance with 13‐cis‐retinoic acid (cis‐RA) demonstrated a desirable 5‐year OS and EFS of 65.6% and 58.3%, respectively. Poorly or undifferentiated tumor histology and cis‐RA administration were independent factors associated with relapse and survival outcomes, respectively (p < .05).Conclusion: A combination of HSCT and cis‐RA successfully improved the outcomes of patients with HR‐NBL in immunotherapy inaccessible settings.
- 13 May 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 69 (9) , e29757
Treatment outcomes among high‐risk neuroblastoma patients receiving non‐immunotherapy regimen: Multicenter study on behalf of the Thai Pediatric Oncology Group
Background: Neuroblastoma is the most common extracranial malignant solid tumor during childhood. Despite intensified treatment, patients with high‐risk neuroblastoma (HR‐NBL) still carry a dismal prognosis. The Thai Pediatric Oncology Group (ThaiPOG) proposed the use of a multimodality treatment to improve outcomes of HR‐NBL in non‐immunotherapy settings.Methods: Patients with HR‐NBL undergoing ThaiPOG protocols (ThaiPOG‐NB‐13HR or ‐18HR) between 2013 and 2019 were retrospectively reviewed. Patient demographic data, treatment modalities, outcomes, and prognostic factors were evaluated and analyzed.Results: A total of 183 patients with HR‐NBL undergoing a topotecan containing induction regimen were enrolled in this study. During the consolidation phase (n = 169), 116 patients (68.6%) received conventional chemotherapy, while 53 patients (31.4%) underwent hematopoietic stem cell transplantation (HSCT). The 5‐year overall survival (OS) and event‐free survival (EFS) were 41.2% and 22.8%, respectively. Patients who underwent HSCT had more superior 5‐year EFS (36%) than those who received chemotherapy (17.1%) (p = .041), although they both performed similarly in 5‐year OS (48.7% vs. 39.8%, p = .17). The variation of survival outcomes was observed depending on the number of treatment modalities. HSCT combined with metaiodobenzylguanidine (MIBG) treatment and maintenance with 13‐cis‐retinoic acid (cis‐RA) demonstrated a desirable 5‐year OS and EFS of 65.6% and 58.3%, respectively. Poorly or undifferentiated tumor histology and cis‐RA administration were independent factors associated with relapse and survival outcomes, respectively (p < .05).Conclusion: A combination of HSCT and cis‐RA successfully improved the outcomes of patients with HR‐NBL in immunotherapy inaccessible settings.